Weekly channel feed

End­points hon­ors 20 women su­per­charg­ing drug R&D; Omi­cron is a 'stress test' for the next pan­dem­ic; Roche and Genen­tech strike an AI pact with Re­cur­sion; and more

4 years ago

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

4 years ago

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral dis­ap­points; FDA nom­i­nee's in­dus­try ties; and more

4 years ago

Bio­gen’s no good week; In­side gene edit­ing's open se­cret; No­vo Nordisk ab­sorbs RNAi part­ner; Boost­ers for all; and more

4 years ago

J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

4 years ago

Pfiz­er's Covid pill de­liv­ers; All you need to know about Dem­s' drug pric­ing plan; What else can an­ti­sense do?; and more

4 years ago

Lat­est news on Covid vac­cine OK; No­var­tis' 1 win and 1 flop; Eli Lil­ly and the Alzheimer's puz­zle; End of an era for Al­ny­lam; and more

4 years ago

So — that pig-to-hu­man trans­plant; Po­ten­tial di­a­betes cure reach­es pa­tient; Ac­cused MIT sci­en­tist lash­es back; and more

4 years ago

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

4 years ago

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; Chart­ing biotech's Q3; and more

4 years ago

Mer­ck shakes hands with Ac­celeron; Fi­nal­ly, a pill for Covid-19; The past and fu­ture of con­tract re­search; and more

4 years ago

DE­VEL­OP­ING News: Ac­celeron ne­go­ti­at­ing $11B buy­out; 11 promis­ing biotech star­tups; Changes ga­lore at No­var­tis; #ES­MO21 high­lights; and more

4 years ago

Lat­est news: It’s a no on uni­ver­sal boost­ers; Pa­tient death stuns gene ther­a­py field; In­side Tril­li­um’s $2.3B turn­around; and more

4 years ago

Sanofi places new $1.9B bet even as its last sours; Sam Wak­sal's new biotech ideas; Cell ther­a­py time for Roche; and more

4 years ago

Abrupt FDA ex­its spark con­cern; Un­pack­ing key con­cepts at gene ther­a­py sum­mit; 20 lu­mi­nar­ies who re­shaped R&D; and more

4 years ago

The past and fu­ture of an­ti­bod­ies, as told through HIV; An­oth­er big phar­ma joins CD47 game; and more

4 years ago

Vac­cine man­dates, bio­phar­ma edi­tion; Alzheimer’s rip­ple ef­fect; Change of guard at J&J; and more

4 years ago

Lat­est news on Fri­day af­ter­noon CRL; A big no to Aduhelm; Re­mem­ber­ing Tachi with Jim Wil­son and Bill Clin­ton; and more

4 years ago

Biotech grieves over Tachi’s pass­ing; $3 tril­lion mi­rage?; Sanofi has a new Pompe drug; and more

4 years ago

Not all mR­NA vac­cines are cre­at­ed equal. Does it mat­ter?; Neu­ro is back; Pri­vate M&A af­fair; and more

4 years ago

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

4 years ago

Bio­gen pressed against the wall as more stake­hold­ers side against Aduhelm; Prime time for CRISPR 3.0?; and more

4 years ago

Storm brews around Aduhelm as FDA re­quests probe; Dis­sect­ing pipeline dis­as­ters; Bob Nelsen is go­ing Re­al­ly Big; and more

4 years ago

Watch out, Pfiz­er and Mod­er­na; An­ti-ag­ing break­through in mice?; Neu­ro for the new GSK; and more

4 years ago
First page Previous page 56789 Next page Last page
A service from the Financial Times